Edit Target: 241
Erastin is often referred to as a "metabolic inhibitor" or a "ferroptosis inducer", rather than a traditional chemotherapy agent.
Erastin is primarily available as a research chemical—it's not an approved therapeutic for clinical use.
Pathways:
-Erastin inhibits system xCT, thereby reducing cystine uptake. This leads to decreased intracellular cysteine, a precursor for GSH. As a consequence, the cell’s glutathione levels drop, compromising its ability to neutralize reactive oxygen species (ROS).
-Glutathione (GSH) Depletion and Increased Oxidative Stress
-Voltage-Dependent Anion Channels (VDACs): Altering VDAC function can affect mitochondrial metabolism, leading to changes in energy production and further enhancing oxidative stress.